Nuzyra (Omadacycline Tosylate) Patent Expiration, LOE Window & CMS Spending

Nuzyra (Omadacycline Tosylate) by Paratek: FDA Orange Book core substance LOE 2030-09-23 (last listed 2037-10-31), 0 AB generics, $126.2M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorParatek
FDA Application & PathwayN209816 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2030-09-23
Last Listed Patent or Exclusivity Date2037-10-31
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$126.2M
2024 Medicare Part D Spend$106.6M
2024 Medicaid Spend$19.5M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 23.5% 2-yr change)